Alzheimer's disease (AD) is a neurodegenerative disorder that accounts for nearly 70% of
the more than 46 million dementia cases estimated worldwide. Although there is no cure for …

Dementia diseases are increasing rapidly, according to the World Health Organization
(WHO), becoming an alarming problem for the health sector. The electroencephalogram …

Subtle changes in fine motor control and quantitative electroencephalography (qEEG) in
patients with mild cognitive impairment (MCI) are important in screening for early dementia …

Alzheimer's disease (AD) is one of the most common and fastest growing
neurodegenerative diseases in the western countries. Development of different biomarkers …

A new EEG-based methodology is presented for differential diagnosis of the Alzheimer's
disease (AD), Mild Cognitive Impairment (MCI), and healthy subjects employing the discrete …

We propose a novel classification framework to precisely identify individuals with
Alzheimer's disease (AD) or mild cognitive impairment (MCI) from normal controls (NC). The …

Aiming to differentiate between mild cognitive impairment (MCI) patients and elderly control
subjects, this study proposes an integrated framework based on spectral-temporal analysis …

Alzheimer disease is one of the most common and fastest growing neurodegenerative
diseases in the western countries. Development of different biomarkers tools are key issues …

Access to affordable, objective and scalable biomarkers of brain function is needed to
transform the healthcare burden of neuropsychiatric and neurodegenerative disease …

Mild cognitive impairment is associated with many neurodegenerative diseases. It is
essential to detect mild cognitive impairment on time to reduce the prevalence of such …